LARGO, Fla.–(BUSINESS WIRE)–BioDerm, Inc. (“BioDerm” or the “Company”), a leading provider of disposable medical devices and wound care supplies to patients with chronic conditions, announced it has received a strategic investment from Denver-based middle market private equity firm, Mountaingate Capital (“Mountaingate”). With its new partner, BioDerm plans to accelerate its organic growth and pursue acquisitions that will expand its product and service offerings for patients.
For over two decades, BioDerm’s proprietary Men’s Liberty external hydrocolloid catheter has pioneered innovative and high performance solutions for male urinary incontinence. In addition to its portfolio of hydrocolloid products for urinary incontinence management, securement and skin protection formulations, the Company provides specialized driveline exit surgical dressing kits for patients with ventricular assist device implants.
“We are very excited to partner with Mountaingate as we focus on our next phase of growth,” said Gaet Tyranski, CEO of BioDerm. “Mountaingate brings extensive industry experience that we can leverage to further advance our business and meet the growing needs of our patients.”
“We chose Mountaingate because of the strong alignment of culture, commitment to founder management and their proven track record of investing in businesses they acquire and helping companies of our size scale,” added Gary Damkoehler, Chairman and shareholder.
“Under Gary and Gaet’s leadership, BioDerm has significantly expanded its product and market reach while demonstrating a high level of service and commitment to the patients they serve. We are delighted that they chose to partner with us and we welcome Gary’s continued investment and Board role,” said Stew Fisher, Mountaingate Managing Director.
Mountaingate is a leading buy-and-build focused middle market private equity firm based in Denver, CO, and was recently named one of the Top 50 best Private Equity Firms for Entrepreneurs by Inc. for the second year in a row. The investment in BioDerm marks the tenth platform investment for Mountaingate in its debut fund, all of which are supporting founder and entrepreneur run businesses.
BioDerm was advised by Piper Sandler & Co. and law firm Akerman LLP, while Mountaingate was advised by law firm Hogan Lovells US LLP. Abacus Finance Group, LLC and Five Points Capital provided additional financing for the transaction.
BioDerm, Inc. headquartered in Largo, Fl., is one of the nation’s leading manufacturers of proprietary hydrocolloid products for urinary management, securement, infection control and skin protection. The Company also provides custom wound care daily dressing change kits to patients with ventricular assist devices installed due to heart failure. BioDerm challenges accepted inferior standards of care by creating and distributing products that reduce infection rates, add comfort and reliability, and vastly improve quality of life.
Mountaingate Capital, based in Denver, CO, is a private equity firm that specializes in building and empowering companies with strong growth potential and engaged leadership teams. The firm was launched by a team of partners with deep investment expertise in four distinct market sectors: marketing services, business/industrial services, specialty distribution and specialty manufacturing. Mountaingate’s focus on organic growth coupled with its proven customer-centric buy-and-build approach for add-on acquisitions and shared equity ownership with management creates more value for the end customer, while forging stronger, more collaborative, and more successful investment partnerships with management teams. For more information on Mountaingate, please visit www.Mountaingate.com.
Stew Fisher, Managing Director